YingweiChen Ph.D.

Dr. Yingwei Chen is a biologist whose practice focuses on patent prosecution in the biotechnology and pharmaceutical industries.

Prior to joining Jones Day, Yingwei was a principal scientist for more than seven years at a biotechnology company, where she was a designated "key personnel" in several projects funded by the National Institutes of Health (NIH). Her work focused on engineering proteins for uses in macromolecule manufacturing, medical diagnostics, and cancer therapy. She was also involved in product commercialization and business development.

During her post-doctoral fellowship at the NIH, Yingwei investigated protein properties related to eye diseases by approaches of biophysics and computation. She also received training at the NIH Office of Technology Transfer, where she advised scientists on proposals. During her Ph.D. education, she led the antibody group in a national lab, where she co-developed antibodies, diagnostic kits, and vaccines for infectious diseases caused by influenza virus, HCV, HEV, and HPV. She also served as an inspector in a vaccine phase III clinical trial, where more than 110,000 volunteers were vaccinated. She is first author of several peer-reviewed scientific publications in journals such as Nature Communications Biology and Protein Science.

In addition, she served as a student attorney for the Vaccine Injury Litigation Clinic at The George Washington University Law School, representing clients before the U.S. Court of Federal Claims.